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Abstract
Metabolic profiling through targeted quantification of a predefined subset of metabolites, performed by mass
spectrometric analytical techniques, allows detailed investigation of biological pathways and thus may provide
information about the interaction of different organic systems, ultimately improving understanding of disease risk
and prognosis in a variety of diseases. Early risk assessment, in turn, may improve patient management in regard to
cite-of-care decisions and treatment modalities. Within this review, we focus on the potential of metabolic profiling
to improve our pathophysiological understanding of disease and management of patients. We focus thereby on
lower respiratory tract infections (LRTI) including community-acquired pneumonia (CAP) and chronic obstructive
pulmonary disease (COPD), an important disease responsible for high mortality, morbidity and costs worldwide.
Observational data from numerous clinical and experimental studies have provided convincing data linking metabolic
blood biomarkers such as lactate, glucose or cortisol to patient outcomes. Also, identified through metabolomic
studies, novel innovative metabolic markers such as steroid hormones, biogenic amines, members of the oxidative
status, sphingo- and glycerophospholipids, and trimethylamine-N-oxide (TMAO) have shown promising results. Since
many uncertainties remain in predicting mortality in these patients, further prospective and retrospective observational
studies are needed to uncover metabolic pathways responsible for mortality associated with LRTI. Improved
understanding of outcome-specific metabolite signatures in LRTIs may optimize patient management strategies,
provide potential new targets for future individual therapy, and thereby improve patients’ chances for survival.
Keywords: Lower respiratory tract infection, Pneumonia, Chronic obstructive pulmonary disease, Mortality
prediction, Steroid hormones, Biogenic amines, Trimethylamine-N-oxide, Intermediates energy metabolism,
Monosaccharides, Oxidative status, Glycerophospholipids, Sphingolipids, Acylcarnitines
Introduction
Metabolomics
The metabolome can be considered the “quantitative
complement of all the low molecular weight molecules
(<1500 amu) in a particular physiological or developmen-
tal state“ of a cell, tissue or organism [1]. Metabolomics is
defined as “the analysis of the whole metabolome under a
given set of physiological, environmental and/or clinical
conditions“ [2]. Metabolite profiling through targeted
quantification of a predefined subset of metabolites of the
metabolome [3] allows analysis of metabolic pathways,
thereby clarifying the interaction of different organic sys-
tems. While proteomics is the study of proteins made by
the organism and the conditions under which the organ-
ism makes them, metabolomics is a more systematic study
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Mass spectrometry (MS) is a sensitive tool that charac-
terizes and quantifies metabolites in a biological sample
[4]. Since metabolomics requires proper separation of
the different compounds to be analyzed, chemical separ-
ation techniques such as gas chromatography (GC) and
liquid chromatography (LC) or capillary electrophoresis
(CE) can be combined with MS detection. Analytical tech-
niques such as LC-MS, GC-MS, CE-MS, and matrix-
assisted laser desorption ionization-MS (MALDI-MS)
may therefore expand coverage of the metabolome [5].
MS is now a routine diagnostic instrument in clinical
laboratories [6].
Biological information derived from these techniques
can provide accurate and clinically useful diagnostic
capability for the management of diseases [7, 8] by
mapping disease risk to metabolic pathways [9]. Previ-
ously, many studies have focused on risk prediction in
patients with lower respiratory tract infections (LRTI)
including community-acquired pneumonia (CAP) and
case (COPD) because such information may have direct
consequences in patient management [10–13]. Early risk
prediction may improve site-of-care decisions (i.e., ICU
treatment vs. hospital ward vs. outpatient) as well as treat-
ment modalities (i.e., antibiotic drugs) [11, 14, 15]. Indeed,
improved understanding of metabolic interactions in LRTI
patients may enhance prediction of outcomes and provide
targets for individual therapy, which in turn could facili-
tate personalized patient management (Fig. 2) [16–18].
Prediction of mortality in community-acquired
pneumonia
CAP is the leading cause of infectious death [19], and of
high mortality, morbidity, and costs worldwide [20–22].
Patients with CAP manifest high short-term mortality
[23, 24] but also substantial long-term morbiditiy [25–28].
To predict all-cause mortality within 30 days, the pneu-
monia severity index (PSI) is a validated tool that cate-
gorizes CAP patients within distinct risk classes (I-V)
[29]. In Europe, the CURB-65 score (Confusion, Urea,
Respiratory rate, Blood pressure, Age >65 years) is used
for the same purpose [30]. Several clinical studies show
that measuring specific inflammatory or metabolic
blood biomarkers, including among others proadreno-
medullin (proADM) [14, 15, 31–33] and procalcitonin
(PCT) [26, 34–36], provides prognostic information
and possibly improves short-term risk stratification and
management decisions in CAP compared to the use of
clinical risk scores alone [37]. Pneumonia not only in-
creases short-term mortality; clinical trials also found
greater long-term mortality rates in patients who sur-
vived an initial CAP episode, compared to the general
population and to patients who have other infections
[28, 38, 39]. These observations suggest that CAP is a
poor prognostic indicator of long-term outcomes.
Particularly, it has been hypothesized that cardiovascu-
lar events that are triggered by an episode of respira-
tory infection may be responsible for the excess
mortality observed in large long-term CAP cohorts. For
this reason, cardiovascular biomarkers (such as natri-
uretic peptides) may also help in the identification of
high risk LRTI patients who need close monitoring and
follow-up [28]. The metabolomics approach for LRTI thus
may also look into metabolites that have been linked to
cardiovascular disease as these conditions are being linked
very closely.
Prediction of mortality in patients hospitalized with
exacerbated chronic obstructive pulmonary disease
Prediction of outcomes in chronic obstructive pulmon-
ary disease (COPD) is challenging. Three published ob-
servational studies suggest that the inflammatory blood
biomarker ProADM independently predicts medium-
term all-cause mortality in patients with stable [40, 41]
or exacerbated COPD. Additionally, measurement of
ProADM combined with the clinical parameters of body
mass index, airflow obstruction, dyspnea and exercise
capacity index (BODE) [42] improves the predictive
power of medium-term all-cause mortality compared to
the use of BODE alone [40]. A recent observational clin-
ical cohort study demonstrated that ProADM levels are
independent predictors of 5- to 7-year all-cause mortal-
ity, and may enhance long-term prognostic accuracy of
demographic and clinical variables in patients hospital-
ized for exacerbation of pneumonic or non-pneumonic
COPD [32]. Similar to CAP, in COPD cardiovascular
disease may be responsible for large portions of the high
mortality associated with this disease. Again, the meta-
bolomic approach in COPD may therefore also consider
interesting metabolites associated with adverse cardio-
vascular outcomes.
Aims of the review and methodology
The goal of the present review is to investigate wether
new metabolic blood biomarkers help optimizing identifi-
cation of patients at risk for poor outcome in CAP and
exacerbated COPD. We discuss nine metabolite classes:
steroid hormones, biogenic amines, intermediate energy
metabolism, monosaccharides, trimethylamines, oxidative
status, sphingolipids, glycerophospholipids, and acylcarni-
tines. Each section will begin with a brief description of
pathways and known physiological effects, followed by a
summary of observational data regarding the analyte’s role
in predicting all-cause mortality. We focus on patients
with LRTI which is responsible for high mortality,
morbidity and costs worldwide. Yet, if no data are
available in strictly LRTI patients, we also discuss these
markers in other diseases namely cardiovascular disease
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which may account for a large proportion of deaths attrib-
utable to LRTI.
Literature discussed in this review was in part identified
through a systematic literature search of English-language
publications indexed in PubMed in March 2015 under the
terms “lower respiratory tract infection” or “pneumonia”
or “chronic obstructive pulmonary disease” combined
with “mortality” with or without “prediction” and/or “car-
diovascular risk” together with any of the terms “steroid
hormones” or “biogenic amines” or “trimethylamine-N-
oxide” or “intermediates of energy metabolism” or “oxida-
tive status” or “monosaccharides” or “sphingolipids” or
“glycerophospholipids” or “acylcarnitines”. Additionally,
more specific keywords were used: “aldosterone”, “andro-
stenedione”, “androsterone”, “corticosterone”, “cortisol”,
“cortisone”, “dehydroepiandrosterone”, “11-deoxycortico-
sterone”, “dihydrotestosterone”, “11-deoxycortisol”, “dehy-
dro-epiandrosterone-sulfate”, “betaestradiol”, “estrone”,
“eiocholanolone”, “17-alpha-hydroxyprogesterone”, “pro-
gesterone”, “testosterone”, “acetylornithine”, “asymmetric
dimethylarginine”, “symmetric dimethylarginine”, “alpha-
aminoadipic acid”, “carnosine”, “creatinine”, “histamine”,
“kynurenine”, “methioninesulfoxide”, “nitrotyrosine”, “cis-
4-hydroxyproline”, “trans-4-hydroxyproline”, “phenyleth-
ylamine”, “putrescine”, “sarcosine”, “serotonin”, “spermi-
dine”, “spermine”, “taurine”, “dopamine”, “DOPA”,
“lactate”, “3-phosphoglycerate”, “alpha-ketoglutaric acid”,
“adenosine-3′,5′-cyclic monophosphate”, “arginine”,
“aspartate”, “dihydroxyacetonephosphate”, “fumarate”,
“glutamate”, “hexose”, “hexosephosphate”, “pentosepho-
sphate”, “pyruvate”, “succinate”, “tetrosephosphate”, “hex-
oses”, “glutathione”, “glutathione-disulfide”, “cysteine”,
“cystine”, “homocysteine”, and “homocystine”. Additional
systematic reviews of the topic were included if they pro-
vided new insights and evidence. As shown in Fig. 1, 4722
of 4773 articles were excluded due to duplication, absence
of full text or inappropriate contents. Letters and case
reports were also excluded.
Promising metabolic biomarkers for prediction of
all-cause mortality
Steroid hormones
Pathway and physiological role
Only few tissues contribute substantially to de novo
steroid biosynthesis: primarily the adrenal glands, the
gonads, and the placenta [43]. All steroid hormones are
derived from cholesterol. Cholesterol enters the cell via
lipoprotein-binding and is stored in cytoplasmic vacu-
oles. After binding of adrenocorticotropic hormone
(ACTH) to its receptor (melanocortin receptor type 2,
MC2R) on adrenal cells, cholesterol is mobilized and
thus available for steroid synthesis. Follicle-stimulating
hormone (FSH) is critical in estradiol synthesis before
and during ovulation and Luteinizing hormone (LH)
for synthesis of progesterone. In the placenta, steroid
biosynthesis is dependent on human chorionic gonado-
tropin (hCG) in early gestation [43].
One of the first measurable physiopathological reac-
tions to infection is the activation of the hypothalamo-
pituitary-adrenal (HPA) axis via stimulation of the cen-
tral noradrenergic stress system by cytokines and other
mediators that are released in response to inflammation
[44–46]. Under healthy conditions, cortisol secretion is
synchronized with dehydroepiandrosterone (DHEA) in
response to the release of ACTH and corticotropin-
releasing hormone (CRH), whereas in critically ill patients
the circadian pattern of cortisol is lost [47] and DHEA
and dehydroepiandrosterone-sulfate (DHEA-S) decrease
[48]. Although the physiological role of DHEA and
DHEA-S is not completely understood, there are clear
indications that they modulate the immune response and
influence proinflammatory and anti-inflammatory cyto-
kine release [48–52]. In severely ill pneumonia patients,
an intra-adrenal shift from DHEA-S to cortisol production
occurs, which might be a potentially life-saving process
during critical illness and thus important for survival in
CAP [53]. Estradiol induces activation of macrophages
and production of proinflammatory cytokines and chemo-
kines from inflammatory cells [54–56], and testosterone
has suppressive effects on immune responses, thereby
inducing increased suceptibility to infection [57]. In auto-
immune diseases progesterone shows proinflammatory
and anti-inflammatory effects [58].
Current research (Table 1)
Table 1 lists several studies reporting that increased cor-
tisol (free and total) levels measured at initial hospital
presentation are independent predictors of in-hospital
and short-term all-cause mortality in hospitalized pa-
tients with mild to severe CAP [53, 59–62]. Interestingly,
Fig. 1 Study flow diagram
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Table 1 Summary of selected literature relevant to steroid hormones in all-cause mortality prediction
First author,
year, reference
Marker Study type Study population Key findings Limitations
Mueller et al.,
2014, [53]
- Cortisol Single-center, prospective
observational cohort study
(6-week follow-up)/secondary






- In age and gender adjusted logistic regression
analysis, cortisol (OR: 2.8; 95 % CI: 1.48–5.28,
p = 0.002) and DHEA (OR: 2.62; 95 % CI:
1.28–5.34, p = 0.008), but not DHEA-S and
none of the different ratios (cortisol/DHEA,
cortisol/DHEA-s, DHEA/DHEA-S) were
associated with increased 6-week all-cause
mortality; the discriminatory accuracy in ROC
analysis (AUC) to predict mortality was 0.74
(95 % CI: 0.60–0.88) for cortisol, 0.61 (95 % CI:
0.46–0.75) for DHEA and 0.72 (95 % CI:
0.62–0.81) for the PSI
- Single-center study
- DHEA - Secondary chart analysis of remaining blood
samples; the study had not been prospectively
designed to use adrenal hormone concentrations
as a primary endpoint [139]
- DHEA-S - Cortisol, DHEA-S and DHEA levels were measured




- Free cortisol Single-center, prospective
observational cohort study
(6.9 +/− 1.9-week follow-up)/




patients presenting to the
emergency department
with CAP
- Initial TC and FC levels were significantly
higher in non-survivors than in survivors
(p < 0.001 for TC and p = 0.004 for FC); the area
under the receiver operating characteristic
curve (AUC) to predict death was 0.76 (95 %
CI, 0.70–0.81) for TC and 0.69 (95 % CI,
0.63–0.74) for FC, whereas the AUC of the PSI
was 0.76 (95 % CI, 0.70–0.81) to predict
mortality
- This study had not been prospectively designed
to use cortisol concentrations as a primary
endpoint, and only single initial cortisol levels
were measured [139]
- Total cortisol - The prognostic accuracy of FC was not higher
than the one for TC (p = 0.12)
- Cortisol levels were measured at different
timepoints during the day
- No assessment of adrenal function- TC and FC levels were independent mortality
predictors in pneumonia; the prognostic
accuracy of total cortisol equaled the








patients, recruited from a
multicenter national
CAP-study in Germany
- After a follow-up period of 30 days initial
serum cortisol levels were significantly higher
in non-survivors than in survivors (p < 0.001);
the AUC to predict 30-day mortality was 0.70
(cut-off serum cortisol value 795 nmol/l)
- No correction for concomitant steroid
medication, due to absent data
- Predictive accuracy of the CURB-65 score alone
(AUC 0.76) was significantly improved by
combining with serum cortisol levels (AUC
0.81, p = 0.001)
- Since blood samples were taken at time of first
contact, cortisol levels were measured at
different time points during the day; however,
during infectious diseases and thus increased
stress levels the circadian pattern of cortisol
production is often lost [140]- Survival analysis by Kaplan-Meyer curves
demonstrated a significantly different survival
within cortisol-quartiles (p < 0.001), which
persisted within individual CURB-65 classes
(p = 0.002–0.003).
- No assessment of adrenal function
Kolditz et al.,
2010, [61]





- After a follow-up period of 30 days cortisol
was significantly higher in non-survivors
compared to survivors (p = 0.009) and was an
independent predictor of short-term mortality
(OR 1.002, 95 % CI 1.000–1.004, p = 0.04)











Table 1 Summary of selected literature relevant to steroid hormones in all-cause mortality prediction (Continued)
- DHEA - The prognostic accuracy of serum cortisol
(AUC 0.83 (0.62–1.0); cut-off serum cortisol:
734 nmol/l) was similar to that of the PSI
(AUC 0.86 [0.75–0.97]) and superior to that
of the CURB-65 score (AUC 0.68, 95 % CI
0.50–0.85) in predicting 30-day mortality
- Single-center study
- DHEA-S - No measurements of serum levels of free cortisol
- Cortisol, DHEA and DHEA-S levels were measured
at different timepoints during the day, which
could limit the prognostic accuracy of one single
cortisol value- Serum cortisol levels were independent 30-day
mortality predictors in pneumonia, whereas
DHEA and DHEA-S showed no significant
difference between survivors and non-survivors
(p = 0.16 and p = 0.70)









72 patients with severe
CAP admitted to the ICU
- TC levels were significantly higher in non-
survivors compared to survivors (p = 0.003 for
TC), whereas postcorticotropin cortisol levels
and Δ-cortisol achieved no significant
difference between survivors and nonsurvivors
(p≥ 0.05, exact value not shown)
- Small sample size with a mortality rate of only
16.7 % (12 patients), leading to low statistical
power
- Increases in mortality rates were observed
across all quartiles of baseline TC levels
- Single-center study
- The AUC to predict mortality was 0.77 (95 %
CI, 0.64–0.90; p = 0.002; cut-off 25.7 μg/dl) for
TC, 0.60 for delta-cortisol (95 % CI 0.42–0.78;
p = 0.24), 0.58 for postcorticotropin cortisol
(95 % CI 0.43–0.74; p = 0.33), 0.71 for CURB-65
(95 % CI 0.57–0.86; p = 0.01) and 0.71 for
APACHE II score (95 % CI 0.56–0.86; p = 0.01),
whereas baseline TC achieved a significantly
higher AUC than postcorticotropin cortisol
(p = 0.03)
- No data about patients with severe
immunosuppression
- No measurement of free cortisol levels
- Kaplan-Meier curves demonstrated serum
baseline cortisol (TC) concentration of
>25.7 μg/dl on presentation to have a
significantly higher risk of death (log rank test,
p < 0.001) compared to baseline cortisol levels
below this cut-off (p = 0.019)
- Measurement of cortisol levels at different
timepoints during the day, potentially limiting
the prognostic accuracy of one single cortisol
value
- Potential confounding due to treatment with
corticosteroids in the study population
- In univariate analysis, baseline cortisol,





- Total cortisol Experimental, prospective
animal study (96-hour
follow-up)
101 canine suffering from
S. aureus pneumonia-
induced sepsis
- At 10 h after onset of sepsis total and free
cortisol levels and change in cortisol levels
after exogenous ACTH administration (delta
cortisol) showed no significant difference
between survivors and non-survivors (p = 0.75
for TC, p = 0.80 for FC, p = 0.64 for delta
cortisol after ACTH stimulation), whereas ACTH
levels correlated significantly, but weakly, with
mortality 10 h after onset of sepsis (p = 0.04)
- Low sample size
- Free cortisol - Cortisol responses may partly be attributed to
sedation, intubation, mechanical ventilation, and











Table 1 Summary of selected literature relevant to steroid hormones in all-cause mortality prediction (Continued)
- At 24 h total and free cortisol, ACTH levels as














- Low levels of DHEA-S and DHEA (quartile 1 vs.
quartiles 2–4) predicted all-cause mortality
(multivariate adjusted HR 1.54, 95 % CI
1.21–1.96 for DHEA-S; HR 1.48, 95 % CI
1.17–1.88 for DHEA)
- Single measurement of DHEA and DHEA-S at
different timepoints during the day with
subsequent possible diurnal variation in serum
DHEA and DHEA-S levels
- DHEA-S
- Age-adjusted risk of all-cause mortality was
increased in men within Q1 of DHEA and
DHEA-S levels compared with men within the
individual quartiles 2, 3 and 4 (Q2, Q3, Q4)
(Q1: HR 1.00 (referent); DHEA: Q2 vs. Q1 HR
0.69, Q3 vs. Q1 HR 0.66, Q4 vs. Q1 HR 0.60;
DHEA-S: Q2 vs. Q1 HR 0.69, Q3 vs. Q1 0.71,
Q4 vs. Q1 0.60)
- No data about treatment with corticosteroids or
other hormones, which might alter mortality risk






38.2 +/− 20.4 months)
200 CKD patients (men)
on hemodialysis (HD)
more than 6 months
- Low plasma DHEA-S levels (cut-off 790 ng/ml)
showed significant association with increased
all-cause mortality (HR 3.667, 95 % CI 1.710–
7.909; p = 0.001) in hemodialysis men, but not
in women (data not shown)
- Single-center study
- No assessmet of testosterone levels as a
precursor of DHEA-S
- Multivariate Cox regression analysis adjusted
for age, comorbidities such as diabetes
mellitus, chronic heart failure, COPD, CRP as
well as for albumin and creatinine
demonstrated an independent association
between low plasma DHEA-S levels and
all-cause mortality in HD men (HR 2.93, 95 %
CI 1.09–7.89; p = 0.033)










- Serum levels of progesterone and estradiol
were significantly higher in non-survivors
compared to survivors (p < 0.001), whereas
testosterone levels were similar in both
groups (p = 0.74)
- Single-center study
- Progesterone - Most of the patients participating in the study
were male
- Testosterone - The discriminatory accuracy in ROC analysis
(AUC) to predict 28-day mortality was 0.87
(p < 0.001) for the APACHE II score (cut-off 26
points), 0.705 (p < 0.001) for estradiol (cut-off
40 pg/ml), 0.713 (p < 0.001) for progesterone
(cut-off 1.03 ng/ml) and 0.518 (p = 0.74) for
testosterone (cut-off 4.4 ng/ml)
- No enrollment of premenopausal women
- Blood sample collection for hormone
measurements only on the first day of septic
shock (no investigation of the dynamic of serum








1032 men in the
Cardiovascular Health
Study (CHS)
- Adjusted for age and cardiovascular risk
factors, low DHT (<25 ng/dl) and cFDHT
(<0.13 ng/dl) levels showed significant
associations with higher all-cause mortality,
even if adjusted for cardiovascular risk factors
(HR 1.31, 95 % CI 1.04–1.65 for DHT; HR 1.72,
- Only one single testosterone measurement
- Time of day for blood collection was not
standardized; however, the effects of these
varying time points of blood collection might be
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95 % CI 1.25–2.37 for calculated free DHT;
p < 0.001 for both)
testosterone levels in older men and no
significant circadian variation of DHT levels [141]
- Calculated free
testosterone
- TT and cFT as well as SHBG were not
significantly associated with all-cause mortality
(HR 1.05 (0.88–1.25) for testosterone; HR 1.04







Analysis from two German
prospective cohort studies
(DETECT and SHIP trial)
(mean follow-up of 5.5 years)
3942 men - Cox regression analyses adjusted for waist-to-
height ratio, smoking and physical activity
revealed that men with total serum
testosterone levels below the 10th percentile
showed an increased independent risk of all-
cause mortality compared to subjects with
higher hormone levels (HR 1.54, 95 % CI
1.20–1.99, p < 0.01); by additional inclusion of
liver disease, increased blood pressure,
diabetes and hsCRP as confounders the
results were still significant for the 10th
percentile as a cut-off (HR 1.38, 95 % CI 1.06–
1.78, p = 0.02); using the 20th percentile as a
cut-off resulted in no significant difference in
all-cause morality between lower and higher
testosterone levels (unadjusted model: HR
1.25, 95 % CI 0.99–1.57, p = 0.06)
- Only one single serum total testosterone
measurement at baseline
- Blood collection at different timepoints during
the day; however, serum samples showed only
minor differences in testosterone levels collected
before and after noon; therefore the effect of the
diurnal variation seems to be minimal
- In univariate Kaplan-Meier survival analysis
patients with lower serum total testosterone
levels (cut-off: 10th percentile) showed
significantly higher all-cause mortality
compared to subjects with non-low hormone
levels (p < 0.01)
- Use of different assay systems to determine total
testosterone
- No measurement of SHBG and thus no










221 patients with CKD
III-IV, undergoing dialysis
or KTR
- Cox proportional hazards regression showed
significant independant association between
low total testosterone levels and high
mortality rates (p = 0.01)
- Small female sample size
- Single-center study
- DHT - No data about patients with CKD I-II
- Estrone - Low testosterone concentrations were
independent mortality predictors in men,
whereas sex steroid levels in women showed










(secondary chart analysis of
MMAS study) (15.3-year
follow-up)
1686 men aged 40 to
70 years, population-based
randomly sampled
- In multivariate, age-adjusted models TT levels
as well as FT, DHT and SHBG were not
significantly associated with all-cause mortality
- Inclusion of mostly white men of higher
socioeconomic status; thus results may not be
generalizable
- Free testosterone - Categorizing TT, FT, DHT and SHBG into 5
quintiles yielded no significant correlation
with all-cause mortality either (for TT:
reference group (RR = 1): TT≥ 650 ng/dl;













Table 1 Summary of selected literature relevant to steroid hormones in all-cause mortality prediction (Continued)
< 370 ng/dl: RR 1.24 (95 % CI 0.89–1.73);
370–466 ng/dl: RR 1.00 (95 % CI 0.70–1.42);
466–545 ng/dl: RR 1.05 (95 % CI 0.74–1.47);
545–650 ng/dl: RR 1.20 (95 % CI 0.86–1.69)
(p for trend = 0.50))
- Lowest quintile of free testosterone level was
significantly associated with decreased IHD
mortality (p for trend = 0.02) and increased
respiratory disease mortality (p for trend =
0.002);
- In conclusion, TT and FT as well as DHT seem







(5.8 +/− 1.4-year follow-up)
251 postmenopausal
women in the ambulatory
care clinic of a tertiary
cardiology hospital
- Kaplan Meier survival curve showed a
significant association between higher all-
cause mortality in women and low estrone
levels (<15 pg/ml) (p = 0.039)
- Single-center study
- No data about male patients
- Multivariate Cox regression analysis adjusted
for diabetes, body mass index, dyslipidemia,
and family history showed estrone to be the
only independent predictor for all-cause
mortality (OR 0.45 (95 % CI 0.21–0.95);
p = 0.038)
- Only 32 deaths and thus relatively low statistical
power
ACTH adrenocorticotropic hormone, APACHE II Acute Physiology And Chronic Health Evaluation, ApoE apolipoprotein E, AUC area under the receiver operating characteristic curve, CAD coronary artery disease, CAP
community-acquired pneumonia, CAPNETZ network of excellence community-acquired pneumonia, Germany, cFDHT calculated free dihydrotestosterone, cFT calculated free testosterone, CHS Cardiovascular Health
Study, CI confidence interval, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, CURB-65 score new-onset confusion urea >7 mmol/L respiratory rate ≥30 breaths per
minute systolic or diastolic blood pressure <90 mmHg or ≤60 mmHg respectively age ≥65 years (pneumonia/LRTI risk scoring system), CVD cardiovascular disease, DETECT Diabetes Cardiovascular Risk-Evaluation:
Targets and Essential Data for Commitment of Treatment, DHEA dehydroepiandrosterone, DHEA-S dehydroepiandrosterone-sulfate, DHT dihydrotestosterone, FC free cortisol, FT free testosterone, HD hemodialysis, HR
hazard ratio, hsCRP high-sensitive C-reactive protein, ICU intensive care unit, IHD ischemic heart disease, IL-1beta interleukin-1 beta, KTR kidney transplant recipients, LDL low-density lipoprotein, MMAS Massachusetts
Male Aging Study, OR odds ratio, p p-value are statistically significant at p < 0.05, PSI pneumonia severity index, Q quartile, ROC receiver operationg characteristic, RR relative risk, sd-LDL small dense low-density











the predictive accuracy of free cortisol (FC) is equal to
that of total cortisol (TC) in pneumonia, independent of
serum albumin levels [59]. The prognostic accuracy of
cortisol in predicting mortality is equal to that of the
PSI, but higher compared to routinely measured labora-
tory parameters such as CRP, PCT or leukocytes, which
do not show significant differences (p > 0.05) [59–61].
Kolditz et al. observed that serum cortisol levels may no-
ticeably improve the predictive power of the CURB-65
score alone as regards short-term mortality [60, 61].
Salluh et al. demonstrated that compared to baseline
serum cortisol levels, which are proven independent
mortality predictors, neither postcorticotropin cortisol
nor Δ-cortisol has notable predictive power in severe
CAP [62]. A recent animal study of canines suffering
from staphylococcus aureus pneumonia showed that
ACTH stimulation induces a pronounced correlation
between all-cause mortality and cortisol (free and total)
levels and Δ-cortisol [63].
Conflicting results mark studies evaluating the role of
serum DHEA as a mortality predictor. A prospective
clinical trial conducted by Mueller et al. demonstrated
that increased DHEA predicts 6-week mortality in CAP,
whereas blood levels of DHEA-S as well as different ra-
tios between cortisol and DHEA, cortisol and DHEA-S,
and DHEA and DHEA-S shows no significant correl-
ation with all-cause mortality [53]. Contrary to these
findings, Kolditz et al. found no difference in DHEA
levels in non-survivors compared to survivors, whereas
the lack of significance for the ratio between DHEA and
DHEA-S as a mortality predictor accords with the re-
sults of Mueller et al. [53, 61]. Data on patients suffering
from sepsis reveal a noticeable dissociation between cor-
tisol and DHEA in non-survivors compared to survivors,
and from this observation it can be inferred that an in-
creased cortisol/DHEA ratio is a prognostic marker in
sepsis [64]. However, although the cortisol/DHEA ratio
in clinical studies of CAP patients is not significant in
the prediction of mortality, nevertheless, in non-
survivors an increased cortisol/DHEA ratio occurs as a
tendency [53]. In elderly Swedish men, an inverse associ-
ation between serum DHEA and DHEA-S is evident,
whereas low serum DHEA and high DHEA-S levels are
independent predictors of all-cause mortality [65].
Furthermore Hsu et al. demonstrated a marked and
independent association between low levels of plasma
DHEA-S and higher mid-term all-cause mortality in
men with chronic kidney disease (CKD) who were
undergoing hemodialysis [66].
Table 1 depicts the strong association between
increased serum estradiol and progesterone levels and
28-day mortality in patients suffering from pneumonia-
related septic shock, whereas serum testosterone levels
are not noticeably different between survivors and non-
survivors after a 28-day follow-up [67]. A prospective
clinical study of elderly men who were free of cardiovas-
cular disease at the time of blood sample collection,
revealed a significant inverse association between dehy-
drotestosterone (DHT) and calculated free DHT levels
with all-cause mortality during a follow-up period of
9 years, whereas total testosterone and calculated free tes-
tosterone showed no significant correlation with mortality
[68]. Contrary to these findings, Friedrich et al. and Gross-
mann et al. observed that low serum total testosterone
levels in men with and without CKD significantly and in-
dependently predict all-cause mortality [69, 70], whereas
another population-based clinical study of 40- to 70-year-
old men [71] observed no significant association with ei-
ther total or free testosterone, or with DHT in all-cause
mortality in multivariate-adjusted analysis.
In postmenopausal women low estrone levels inde-
pendently predict long-term all-cause mortality [72].
Biogenic amines
I. L-arginine metabolites: Asymmetric dimethylarginine and
symmetric dimethylarginine
Pathway and physiological role Endothelial nitric
oxide synthases (NOS) synthesize nitric oxide (NO) from
L-arginine (Arg). NO is responsible for vasodilatation
and acts as a neurotransmitter with several functions, in-
cluding memory formation [73]. NO promotes relax-
ation of airway smooth muscle in the respiratory system,
but NO deficiency results in hyperreactivity of the air-
way [74]. Asymmetric dimethylarginine (ADMA) and
its isomer symmetric dimethylarginine (SDMA) are
endogenous compounds of methylated protein turn-
over. ADMA—but not SDMA—is a competitive in-
hibitor of NOS and thus indirectly of NO [75]. One
study shows that ADMA is present in the sputum of
COPD patients [76].
Current research (Table 2) A large community-based
study of middle-aged participants revealed a positive
association between ADMA levels and long-term
mortality, whereas the Arg/ADMA ratio was inversely
associated with death rate [77]. In people >65 years,
ADMA is the strongest predictor of all-cause mortal-
ity, while some traditional risk factors—e.g., body
mass index, systolic and diastolic blood pressure, male
sex or triglycerides—lose their predictive power in
this age group [78]. Additionally, elevated ADMA and
SDMA serum levels correlate noticeably with higher
all-cause mortality in patients with stable CHD [79] and
in critically ill patients [80, 81]. Contrary to these findings,
another study—after adjustment for NT-proBNP, hsCRP,
troponin T and cardiorenal indices—reveaed that SDMA,
but not ADMA, is an independent predictor of all-cause
mortality [82].
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- ADMA was positively associated with
mortality (multivariable-adjusted HR 1.21,
95 % CI 1.07–1.37, p = 0.003)
- Only middle-aged subjects
- L-arginine
- Arginin/ADMA-ratio was inversely
associated with mortality (HR 0.80, 95 %
CI 0.69–0.93, p = 0.004)
- Higher ADMA levels (p = 0.0002) and
lower Arg/ADMA-ratios (p = 0.0005) were
associated with elevated mortality in
non-diabetic subjects
Pizzarelli et al., 2013, [78] - ADMA Single-center, prospective
cohort study (median
follow-up of 110 months)
1,025 randomly selected adults
(>65 years) living in Chianti area,
Tuscany, Italy
- Plasma ADMA was a strong predictor of
all-cause mortality (HR 1.26, 95 % CI
1.10–1.44, p < 0.001) and there was a
non-significant trend for cardiovascular
mortality (HR 1.22, p = 0.07) after
multivariate adjusment
- Single-center study
- L-arginine - Only one ethnic population
- There was no association of ADMA with
mortality in subjects with high L-arginine,
but an increase in mortality in those with
normal to low L-arginine








- After adjustment for confounders higher
levels of ADMA (HR 1.15, 95 % CI 0.95–1.37)
and SDMA (HR 1.29, 95 % CI 1.09–1.52) were
associated with an increase in all-cause mortality
- Selection bias
- SDMA - Only two-center study
(KAROLA Study, Germany)
Koch et al., 2013, [80] ADMA Single-center, observational
prospective cohort study
(3-year follow-up)
255 ICU patients and 78 healthy
controls living in Germany
- ICU patients had higher serum ADMA levels
than healthy controls (median 0.48 vs. 0.36





- ICU non-survivors had higher ADMA
levels compared with ICU survivors
(median 0.62 vs. 0.44 μmol/L, p < 0.001)
- Single-center study
- High ADMA levels predicted all-cause mortality
in critically ill patients (p < 0.001)
- ADMA levels increased during 7 days of ICU
therapy (p < 0.001)
Koch et al., 2013, [81] SDMA Single-center, observational
prospective cohort study
247 ICU patients and 84 healthy
controls living in Germany
- ICU patients had higher serum SDMA levels
than healthy controls (median 0.84 vs. 0.38





- ICU non-survivors had higher SDMA
levels compared with ICU survivors












Table 2 Summary of selected literature relevant to biogenic amines in all-cause mortality prediction (Continued)
(3-year follow-up) - High SDMA levels predicted poorer long-term
prognosis in critically ill patients (p < 0.001)
Gore et al., 2013, [82] - SDMA Observational prospective
cohort study (median
follow-up of 7.4 years)
3,523 adults aged 30 to 65 years
(Dallas Heart Study)
- After adjustment for cardiorenal indices,
age, sex, race, NT-proBNP, hsCRP and
Troponin, SDMA, but not ADMA, was
associated with all-cause mortality (HR
1.86, 95 % CI 1.04–3.30, p = 0.01)
- Single blood sampling
- ADMA
Suzuki et al., 2011, [85] - Kynurenine Single-center, observational
prospective cohort study
129 Japanese patients with CAP
and 64 healthy controls
- CAP patients had elevated levels of Kyn
(p < 0.0001) and reduced levels of Trp
(p < 0.0001) compared with healthy controls
and thus higher Kyn/Trp ratios (p < 0.0001)
- Single-center study
- Tryptophan - Small sample size
- No information about
duration of follow-up- Increasing severity of sepsis and CAP (PSI
and CURB-65 score) was associated with higher
Kyn levels, lower Trp levels and higher Kyn/Trp ratios.
- Non-survivors had higher Kyn levels
(p = 0.023) and lower Trp levels (p = 0.032)
and as a result, higher Kyn/Trp ratios
(p = 0.005)
Darcy et al., 2011, [86] - Kynurenine Single-center, observational
prospective cohort study
50 patients from Australia with
severe sepsis (organ dysfunction
or shock), 30 with non-severe
sepsis and 40 hospital controls
- Sepsis patients had elevated levels of Kyn
(p < 0.0001) and reduced levels of Trp (p < 0.0001)
and thus higher Kyn/Trp ratios (p < 0.0001)
compared with hospital controls.
- Single-center study
- Tryptophan - Small sample size
- Kyn/Trp ratio was increased in severe
sepsis compared with non-severe sepsis
(p = 0.0006)
(28-day follow-up)
- Kyn/Trp ratio did not differ between survivors
and non-survivors by day 28 of the study (p = 0.2)
Huttunen et al., 2010, [87] - Kynurenine Single-center, observational
prospective cohort study
(30-day follow-up)
132 patients with bacteremia
admitted to Tampere University
Hospital in Finland
- Maximum Kyn/Trp ratios were significantly
elevated in non-survivors (30-day case fatality)
compared with survivors (193.7 vs.
82.4 μmol/mmol; p < 0.001)
- Small sample size
- Tryptophan - Single-center study
Qian et al., 2013, [92] 3-nitrotyrosine Single-center, observational
prospective cohort study
(90-day follow-up)
158 patients with AKI, 12 critically
ill patients without AKI, 15 healthy
controls
- Patients with AKI had higher 3-NT/Tyr levels than
healthy and critically ill controls (p < 0.001)
- Relatively small size study
- Single-center study
- High 3-NT/Tyr was associated with higher 90-day
mortality (p = 0.025)
3-NT 3-nitrotyrosine, ACS acute coronary syndrome, ADMA asymmetric dimethylarginine, AKI acute kidney injury, CAP community-acquired pneumonia, CHD coronary heart disease, CI confidence interval, CURB-65 score
new-onset confusion, urea >7 mmol/L, respiratory rate ≥30 breaths per minute, systolic or diastolic blood pressure <90 mmHg or ≤60 mmHg, respectively, age ≥65 years (pneumonia/LRTI risk scoring system), HR
hazard ratio, hsCRP high-sensitivity C-reactive protein, ICU intensive care unit, KAROLA Langzeitfolge der KARdiOLogischen Anschlussheilbehandlung, Germany, Kyn kynurenine, NT-proBNP pro-B-type natriuretic peptide,












Pathway and physiological role Tryptophan (Trp) is an
essential amino acid. Degradation of Trp to its toxic me-
tabolite kynurenine (Kyn) is catalyzed by the enzyme
indoleamine 2,3-dioxygenase (IDO), which is expressed
in a variety of cells; e.g., monocyte-derived macrophages
and dentritic cells [83]. Moreover, IDO induces inhib-
ition of T-cell proliferation [84] and its activity is mea-
sured by the kynurenine-to-tryptohan ratio (Kyn/Trp
ratio) [85–87].
Current research (Table 2) Subjects with CAP [85] and
sepsis [86] show significantly higher Kyn levels and
lower Trp levels compared to controls. As a result, the
Kyn/Trp ratio, which represents the IDO activity, is ele-
vated in CAP and sepsis [85, 86]. Increased severity of
CAP (defined by PSI and CURB-65 score) [85] and of
sepsis [86] are associated with higher Kyn levels, higher
Kyn/Trp ratios and lower Trp levels. In patients with
CAP [85] or bacteremia [87], short-term non-survivors
have higher Kyn/Trp ratios than do survivors, whereas
the sepsis group manifests no marked difference in Kyn/
Trp ratio between non-survivors and survivors in the
short-term [86].
III. Nitrotyrosine
Pathway and physiological role Homeostatic balance is
usually maintained between the formation of reactive
oxygen species (ROS) and its removal by endogenous
antioxidants. Oxidative stress arises from an imbalance
towards ROS production [88]. Peroxynitrite (ONOO−) is
a potent oxidant of this ROS group and catalyzes nitra-
tion of the non-essential amino acid tyrosine (Tyr) to
the non-proteinogenic amino acid 3-nitrotyrosine (3-
NT) [89]. Accordingly, nitrotyrosine is a characteristic
marker of oxidative stress (e.g., inflammation) [90].
Protein-associated nitrotyrosine is lower in smokers
than in non-smokers, evidence consistent with a lower
production of endothelial NO in cigarette smokers. In
contrast, smokers with COPD show higher average nitro-
tyrosine levels in plasma proteins compared with smokers
without COPD. Therefore, it seems that chronic inflam-
matory processes in COPD patients increase the nitration
of Tyr [91].
Current research (Table 2) As shown in Table 2, sub-
jects with hospital-acquired acute kidney injury (AKI)
have higher 3-nitrotyrosin/tyrosine ratios (3-NT/Tyr)
than do critically ill subjects without AKI and healthy
controls. In the AKI group, the 3-NT/Tyr ratio is posi-
tively associated with 90-day mortality independent of
the severity of illness [92].
Trimethylamine-N-oxide, betaine, choline
Pathway and physiological role Synthesis of phospho-
lipids to build cell membranes, acetylcholine for neuro-
transmission just as the methyl group metabolism
depend on dietary phosphatidylcholine (PC)/choline in-
take [93]. The liver and kidney can both oxidize choline
to betaine. Betaine is an important metabolite in methyl
group metabolism; it functions as a methyl group donor
to form methionine [94, 95]. Eggs, red meat, beef and
chicken liver, wheat germ, bacon, dried soy beans and
pork contain the highest concentration of total choline.
Betaine levels are high in wheat bread, wheat bran,
wheat germ, spinach and shrimp [96]. Intestinal mi-
crobes (gut microflora) transform choline and other qua-
ternary ammonium compounds (e.g., betaine) to the gas
trimethylamine (TMA) [97]. This gas is reabsorbed effi-
ciently into the circulation and then into human liver.
Hepatic flavin-containing monooxygenases (FMOs) rap-
idly oxidize TMA to trimethylamine-N-oxide (TMAO)
[98]. Thus TMA is not produced via intermediary metab-
olism; rather, it depends on intestinal microbial breakdown
of choline and other precursors. Thus for the production
of TMA and its oxidation product TMAO, intact and
functional intestinal microflora are essential [97, 99].
Current research (Table 3) Several animal studies show
the effects of elevated TMAO levels. An increase in the
concentration of plasma TMAO was observed in mice,
which were fed with either choline or TMAO [99, 100].
After 16 weeks of feeding there was a marked increase in
tubulointerstitial fibrosis and serum cystatin C [100]. A
significant positive correlation between plasma levels of
TMAO and atherosclerotic plaque size after 20 weeks of
feeding in both male and female mice was observed.
Furthermore, macrophages from mice supplemented
with either choline, betaine or TMAO showed aug-
mented lipid-loaded macrophages and higher levels of
the macrophage scavenger receptors CD36 and SR-
A1. These receptors implicate atherosclerosis. In a
mouse model, application of broad-spectrum antibi-
otics for 3 weeks suppressed dietary choline-induced
formation of macrophage foam cells and choline-
mediated enhancement in atherosclerosis [99].
In humans (3), higher plasma NT-proBNP [101, 102]
and advanced left ventricular diastolic dysfunction are
associated with elevated plasma betaine, choline and
TMAO. TMAO levels are markedly higher in patients
with heart failure NYHA III/IV or diabetes mellitus.
Baseline plasma levels of TMAO have marked prognos-
tic value for major adverse cardiovascular events in low-
risk subgroups after adjustments for age and cardiorenal
indices [102, 103]. Since cardiovascular disease (CVD)
remains the major cause of deaths [104], these findings
might be predictive of poor outcome. In addition,
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Table 3 Summary of selected literature relevant to trimethylamine-N-oxide in all-cause mortality prediction
First author,
year, reference
Marker Study type Study population Key findings Limitations
Tang et al..,
2015, [102]
TMAO Single-center, prospective observational
cohort-study (5-year follow-up)
112 adults with stable but symptomatic
chronic systolic HF (left ventricular ejection
fraction ≤35 %) (Cleveland Clinic)
- After adjustment for age, eGFR, and NT-proBNP
levels, higher TMAO levels were associated with
poor prognosis (death/transplantation) (HR 1.46;
95 % CI 1.03-2.14; p = 0.03)
- Single-center study
- Selection bias
- TMAO levels were higher in subjects with
higher plasma NT-proBNP levels and NYHA
functional class III or IV (p = 0.02)
Tang et al.,,
2013, [103]
TMAO Single-center, prospective interventional
study (9-day follow-up)
40 healthy adults without chronic illnesses,
active Infections or antibiotic therapy
(Cleveland Clinic)




- Only healthy adults
included
- In 6 adults, plasma levels of TMAO were
markedly suppressed after a weekly therapy
with broad-spectrum antibiotics and reappeared
after withdrawal of antibiotics.
Tang et al.,
2013, [103]
TMAO Single-center, prospective observational
cohort-study (3-year follow-up)
4,007 adults undergoing elective diagnostic
cardiac catheterization without evidence of
an ACS (Cleveland Clinic)
- Elevated plasma levels of TMAO were associated
with a higher risk of a major cardiovascular event
after adjustment for traditional risk factors (p < 0.001)
- Single-center study
- Selection bias
- Prognostic value of elevated plasma levels of TMAO
remained significant in low-risk subgroups
Tang et al..,
2014, [101]
TMAO Single-center, prospective observational
cohort study (5-year follow-up)
720 subjects with a history of HF (Cleveland Clinic) - Subjects with HF (5.0 μmol) had higher median




- TMAO levels were predictive of 5-year mortality risk
after adjustments for traditional risk factors, BNP levels
and eGFR (HR 1.75; 95 % CI 1.07–2.86; p < 0.001)
Tang et al..,
2015, [100]
TMAO Single-center, prospective observational
cohort-study (5-year follow-up)
521 subjects with CKD (eGFR < 60 mL/min) and
3,166 non-CKD subjects (Cleveland Clinic)
- TMAO levels were increased in CKD subjects (median,
7.9 μmol/L) compared with non-CKD subjects (median,
3.4 μmol/L), p < 0.001
- No specific results
for CKD stage 1-2
- Single-center study
- Higher TMAO levels (quartiles 4 versus 1) were
associated with an increase in 5-year all-cause
mortality in CKD subjects (HR 1.93; 95 % CI
1.13–3.29; p < 0.05) and non-CKD subjects after
adjustment for traditional CVD risk factors and
eGFR (HR 1.47; 95 % CI 1.02–3.29; p < 0.05)
ACS acute coronary syndrome, BNP brain natriuretic peptide, CI confidence interval, CKD chronic kidney disease, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HF heart failure, HR hazard ratio,











elevated TMAO levels are predictive of 5-year mortality
risk in subjects with heart failure after adjustment for
cardiovascular risk factors and renal function [101].
In healthy adults a dietary PC challenge raises TMAO
level. In six human participants this elevation was sup-
pressed with oral broad-spectrum antibiotics [103].
A high correlation is evident between plasma and
urine levels of TMAO, which indicates an effective urin-
ary clearance of TMAO [103]. Median TMAO blood
levels in subjects with CKD stage 3 or beyond are mark-
edly higher than in non-CKD subjects. Moreover, there
is a modest correlation between elevated TMAO with
low estimated glomerular filtration rate (eGFR) and high
cystatin C. After adjustment for traditional cardiovascu-
lar risk factors an increased all-cause mortality rate at
5 years for CKD subjects with a higher TMAO level is
evident. In subjects with preserved eGFR (>60 mL/min
per 1.73 m2) higher TMAO levels are associated with
higher 5-year mortality, particularly in patients who have
concomitant high cystatin C levels [100].
Intermediate energy metabolism
Lactate
Pathway and physiological role Glycolysis produces
the metabolite pyruvate. Lactate dehydrogenase (LDH)
converts pyruvate to lactic acid under anaerobic condi-
tions. Lactate acid dissociates spontaneously to lactate
and H+ in aqueous solutions. Thus lactate is the end
product of anaerobic glucose metabolism in erythro-
cytes, perivenous hepatocytes, skeletal myocytes and skin
cells. A normal plasma lactate concentration is 0.3-
1.3 mmol/L and the liver removes 70 % of the lactate.
An imbalance between systemic oxygen demand and
oxygen availability (e.g., hypoperfusion in patients with
sepsis) heightens anaerobic metabolism and results in
lactic acidosis [105, 106].
Current research (Table 4) In children with pneumonia,
relative risk for in-hospital mortality is higher if the lactate
level is above 2 mmol/L [107]. In adults with pneumonia,
lactate level is the better predictor of 28-day mortality
than the CURB-65 score, whereas a combination of
CURB-65 with lactate level improves the predictive value
of CURB-65 alone (Table 4) [108].
Lactate >3.5 mmol/L in combination with a PaO2/FiO2
(PF) ratio <170 is associated with a higher 28-day mor-
tality rate; accordingly, a combination of serum lactate
and the PF ratio may be a useful predictor of mortality
in patients with sepsis, including pneumonia [109].
Metabolic profiling of plasma from 90 critically ill inten-
sive care unit (ICU) patients revealed significantly higher
lactate levels in non-survivors compared with survivors
in 28-day mortality [110].
Monosaccharides
Pathway and physiological role Monosaccharides are
the simplest form of sugar and therefore the most basic
units of carbohydrates; they are important as an en-
ergy resource. The most important monosaccharides
in human metabolism are the three aldohexoses (D-
glucose, D-mannose, and D-galactose), and D-fructose,
a sugar monomer of the ketohexose series of carbohy-
drates [111].
Current research (Table 5) In patients with CAP (Table
5) , hypoglycemia [112] and hyperglycemia are associ-
ated with a higher rate of in-hospital mortality [112,
113] and in-hospital complications [113]. Furthermore,
hyperglycemia is a predictor of death at 28 and 90 days
after admission to hospital in patients with CAP and no
pre-existing diabetes [114].
Oxidative status
Pathway and physiological role Reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) are im-
portant in regulating the proliferation of cells and their
survival. However, a sudden and prolonged surge of
ROS and RNS may contribute to cell death. The redox
homeostasis of cells, which maintains a balance between
the generation and elimination of ROS and RNS ensures
that endogenous and exogenous stimuli are modulated.
Altered redox homeostasis leads to oxidative stress,
which may cause aberrant cell death and the develop-
ment of disease [115]. Glutathione (gamma-glutamyl-
cysteinyl-glycine, GSH) is the predominant antioxidant
non-protein cysteine-containing thiol, which is found in
all animal cells. It is important in maintaining the status
of cellular redox, which is determined by the ratio of the
concentration of oxidizing equivalents to reducing
equivalents [116], and it is the principal intracellular
defense against oxidative stress. GSH has two redox
forms: reduced GSH and glutathione disulfide (GSSG,
the oxidized form) [117]. Cells can excrete GSSG or re-
store it to GSH through the action of GSH reductase.
De novo synthesis of GSH from its amino-acid consti-
tuents—a process that involves two enzymatic steps
catalyzed by glutamate cysteine ligase and GSH synthe-
tase— [118] is essential for the adaptive elevation of
GSH during oxidative stress [117]. The rate-limiting
step in the de novo synthesis of GSH occurs at the cel-
lular level of the amino acid cysteine [119]. Addition-
ally, reduction of cystine to cysteine is an important
mechanism for intracellular GSH elevation in vivo in
lungs [120]. During oxidative stress and inflammation,
synthesis of GSH is upregulated, possibly providing a
protective or adaptive response to subsequent oxidative
and inflammatory stress. An imbalance of antioxidant
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First author,
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Ramakrishna et al., 2012,
[107]
Lactate Single-center, observational prospective
cohort-study (follow-up until hospital discharge)
233 Malawian children with
pneumonia
- The odds ratio for in-hospital mortality
(25 deaths) in children with lactate
>2 mmol/L was 7.48 (95 % CI 1.72–32.6)







Chen et al., 2015, [108] Lactate Single-center, observational prospective
cohort-study (28-day follow-up)
1,641 patients with pneumonia
(861 inpatients, 780 outpatients)
(Emergency Department of Beijing
Chao-Yang Hospital)
- Non-survivors had higher lactate and







- Lactate predicted 28-day mortality better
than CURB-65 score (AUC 0.823 vs. 0.692;
p < 0.01)
- Combination of lactate and CURB-65 score
improved the predictive value of CURB-65 score
alone (AUC 0.851)
AUC area under the receiver operating characteristic curve, CI confidence interval, CURB-65 score new-onset confusion, urea >7 mmol/L, respiratory rate ≥30 breaths per minute, systolic or diastolic blood pressure











Table 5 Summary of selected literature relevant to monosaccharides in all-cause mortality prediction
First author,
year, reference
Marker Study type Study population Key findings Limitations
Foltran et al.,
2013, [112]




- Plasma glucose levels of mean 86 mg/dl (95 % CI, 61–102 mg/dl) were




- No information on
important confounders
(e.g. diabetes)
- The OR was 1.33 (95 % CI 1.07–1.66) for each 10 mg/dl of increase in




Glucose Multicenter, observational prospective cohort
study (median length of in-hospital stay was
6 days, follow-up until hospital discharge)
2,471 Canadian
adults with CAP
- Patients with an admission glucose level >11 mmol/l had an increased
risk of death (13 vs. 9 %, p = 0.03) and in-hospital complications (29 vs.
22 %, p = 0.01) compared to those with glucose levels <11 mmol/l
- Glucose only
measured once
- No examination of
antiglycemic
treatments
- Not measured long-
term glucose (HbA1c)
- Patients with admission glucose >11 mmol/l had 73 % higher mortality
(95 % CI 12–108 %) and a 52 % higher (12–108 %) risk of in-hospital
complications compared to patients with glucose levels ≤6.1 mmol/l
Lepper et al.,
2012, [114]





- In patients with no pre-existing diabetes an increased serum glucose
level was a predictor of death at 28 and 90 days
- Treatment of
pneumonia was left to
the discretion of the
doctor
- Mild hyperglycemia (6-10.99 mmol/l)
on admission was associated with an
increased risk of death at 90 days (HR 1.56,
95 % CI 1.22–2.01, p < 0.001), and this risk
increased to 2.37 (95 % CI, 1.62–3.46,
p < 0.001) when serum glucose levels
were ≥14 mmol/l






- No HbA1c tests
CAP community-acquired pneumonia, CAPNETZ network of excellence community-acquired pneumonia, Germany, CI confidence interval, HbA1c glycated hemoglobin, HR hazard ratio, OR odds ratio, p, p-value are











and proinflammatory genes can lead to chronic inflam-
mation [117].
Homocysteine is built from the breakdown of the es-
sential amino acid methionine and can subsequently be
converted to cystathionine with vitamin B6 and further
to cysteine. Conversely, vitamin B12 promotes remethy-
lation of homocysteine to methionine [121, 122]. The
latter reaction is catalyzed by the enzyme methionine
synthase, requiring 5-methyltetrahydrofolate, the main
circulating form of folate, and vitamin B12 in its co-
factor form methylcobalamin [122].
Current research (Table 6) Table 6 outlines a clinical
study that ascertained the status of glutathione—re-
flected by the reduced ratio of glutathione (GSH) to total
glutathione in whole blood—as an independent mid-term
predictor of all-cause mortality in post-ICU patients,
whereas the total concentration of glutathione as well as
the concentration of GSH alone revealed no association
with 6-month mortality [118]. Although total glutathione
and GSH concentrations in ICU patients have been ob-
served as low, the quartile with the highest redox ratio of
glutathione (GSH/total glutathione) carries the highest
post-ICU all-cause mortality risk [118]. Lower levels of
glutathione-S-bimane (GSB)—that is, intracellular GSH
measured by fluorescence-activated cell sorter (FACS)—in
CD4 T cells are prominent long-term mortality predictors
in HIV-infected individuals, independent of CD4 T cell
count [123].
Several clinical studies have demonstrated that elevated
levels of plasma homocysteine independently predict
long-term all-cause mortality in the elderly [124–127] as
well as in younger adults [128, 129]. In contrast, in pa-
tients after ischemic stroke a marked association is evident
between high plasma homocysteine and overall mortality
only after exclusion of patients with dissection [129]. An-
other study showed a correlation between higher homo-
cysteine levels and increased long-term mortality in the
subgroup of patients with malnutrition and inflammation
[130]. Additionally, elevated plasma homocysteine levels
are discernibly related to a higher death rate only in older
women [126]. Besides their relation to all-cause mortality,
high homocysteine concentrations are independently asso-
ciated with cardiovascular mortality [128].
Glycerophospholipids
Pathway and physiological role Glycerophospholipids
are glycerol-based phospholipids that form the bilayer in
biological membranes. Their basic structure is composed
of glycerol, to which a phosphoric acid and two fatty
acids are attached as esters. An additional alcohol
group (e.g., serine, choline, ethanolamine or inositol) at-
tached to the phosphate allows the formation of distinct
phosphoglycerides. The five classes of glycerophospholipids
are phosphatidylcholine (PC, lecithin), phosphatidylethanol-
amine (PE), phosphatidylserine (PS), phosphatidylinositol
(PI) and diphosphatidylgylcerol (cardiolipin) [131].
Current research (Table 7) In lipid profiling of patients
undergoing coronary angiography, 19 PC and 3 lysopho-
sphatidylcholine (lysoPC) species reveal a noticeable as-
sociation with mortality due to total and coronary artery
disease. Ten of 19 PC and all 3 analyzed lysoPC species
are inversely associated with mortality, whereas PC 32:0
reveals the strongest positive correlation with mortality
[132]. Four lysoPC species—C16:0, C18:0, C18:1, and
C18:2—account for over 90 % of total plasma lysoPC
concentration. The levels of these main lysoPC species
as well as total lysoPC concentrations are markedly re-
duced in sepsis, including pulmonary infections, com-
pared to healthy controls (Table 7). Moreover, 30-day
non-survivors show higher ratios of lysoPC/PC com-
pared with survivors [133].
Sphingolipids
Pathway and physiological role Sphingolipids are es-
sential components of cell membranes, and in neural
tissue they are important in signal transduction and cell
recognition. Fundamental building blocks of sphingoli-
pids are long-chain bases (sphingoid bases). Their
amine group is linked to an acyl group (e.g., fatty acid)
and the backbone of the sphingoid base is linked with
phosphate to an alcohol group (serine, ethanolamine or
choline). The 3 principal forms of sphingolipids are cer-
amide and its derivatives sphingomyelin (SM) and gly-
cosphingolipids [134].
Current research (Table 7) Elevated plasma SM levels
are an independent risk factor for CHD and an outcome
predictor in patients with acute coronary syndrome [135,
136]. In lipid profiling of patients undergoing coronary
angiography, 9 SM species are significantly associated with
total and CHD long-term mortality (Table 7). Of 9 SM
species, 5 showed an inverse association and 4 (specifically
SM 16:0, 16:1, 24:1, and 24:2) displayed a positive associ-
ation with total and cardiovascular mortality [132].
Acylcarnitines
Pathway and physiological role Carnitine (3-Hydroxy-
4-N-trimethylammoniobutanoate) is biosynthesized in
the liver and kidneys from the amino acids lysine and
methionine. Nutrition is an important, but not essential,
source of carnitine. The highest concentrations of carni-
tine are found in red meat, but carnitine is also found in
other foods such as nuts, seeds, legumes, vegetables,
fruits and cereals. Fatty acid oxidation and thus fatty
acid energy metabolism occur in the cellular mitochon-
dria. In the cytosol, free fatty acids are attached with a
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Table 6 Summary of selected literature relevant to oxidative status in all-cause mortality prediction
First author,
year, reference













(>17 years of age)
- After division of patients
into quartiles according to
total concentration of
glutathione and GSH in
whole blood, no relationship
to mortality was observed
(data not shown); division of
patients into quartiles
according to GSH/total
glutathione ratio showed a
significant higher 6-month-
all-cause mortality for the
quartile with the highest
ratio compared to the lower
three quartiles (p = 0.026);
the AUC of GSH/total
glutathione ratio regarding
all-cause mortality prediction
was 0.56 (p = 0.18) with an
optimal cut-off for the GSH/
total glutathione ratio of
0.66; a stepwise multiple
logistic regression analysis
regarding 6-month-mortality
prediction showed an OR of
2.35 (CI 1.02-5.41; p < 0.001)
for the GSH/total glutathione
ratio
- The study only represented the
group actually studied, namely
patients >17 years of age admitted






- Observational studies allow no
statement about causal association
- Redox status of glutathione in
plasma might not be representative
for the intracellular status (Nevertheless,
the plasma ratio of GSH/total
glutathione could be useful as a




























- Logistic regression analyses demonstrated
an association between increased baseline GSB
and improved 2-3-year survival, whereas baseline
GSB levels below normal values showed a higher
mortality (p < 0.0001)
- Selection bias due to exclusion of
patients who finally were trial subjects
of the NAC interventional trial
- GSH
- GSB - No data about plasma glutathione
- Kaplan-Meier survival curves demonstrated that
patients with baseline GSB levels below 1.05 show
a significantly increased 2-3-year all-cause mortality
compared to subjects with higher baseline GSB levels
(p = 0.005); the above named optimal treshold of 1.05
for separating survivors from non-survivors was
determined using ROC analyses for 2-3-year survival
- In proportional hazard analyses with inclusion of
GSB levels as well as CD4 T cell counts in the model,
GSB has still been demonstrated to be a significant,
independent mortality predictor (RR 1.6 [95 % CI
1.1–2.5], p = 0.009), despite its significant correlation












Table 6 Summary of selected literature relevant to oxidative status in all-cause mortality prediction (Continued)
Xiu et al.,
2012, [124]
Prospective observational cohort-study (up to
10-year follow-up)
1,412 elderly






- In a model adjusted for sociodemographic,
behavioral, and nutritional variables, plasma
homocysteine levels >14.5 umol/l were associated
with significantly higher mortality compared to
those <9.3 umol/l (HR 1.8, 95 % CI 1.20–2.71; p = 0.002)
- Although adjustment for several
known associations with homocysteine
status has been undertaken, residual
confounding is still possible
Wong et al.
2013, [125]
Homocysteine Prospective observational population-based









- After adjustment for frailty, age, education,
living circumstances, smoking, cardiovascular
disease, cardiovascular risk factors and renal
function, high total plasma homocysteine
levels (≥15 umol/l) were a significant all-cause
mortality predictor (HR 1.25, 95 % CI 1.06–1.48, p < 0.05)
- Self-selection of study
participants might have






of study results and might
have moved the results





Homocysteine Sub-study of a prospective observational












- After adjustment for several confounders,
women in the third and the fourth quartile
of plasma homocysteine levels were associated
with a significantly higher all-cause mortality
risk compared to those in the first quartile
(Q3 HR 1.70, 95 % CI 1.08–2.65; Q4 HR 1.91, 95 %
CI 1.22–3.00), independently of vitamin B12 status;
in men there was no significant difference in
all-cause mortality rates between different quartiles
of homocysteine levels in adjusted models
- Possible underestimation of the actual
relationship between homocysteine
levels and mortality due to selection
bias, since excluded subjects were
older, more likely to be cognitively
impared, less physically active and had
suffered CVD more often at baseline
Drewes et al.,
2014, [127]





follow-up of 3.2 years)
3,522 subjects










- In the placebo group subjects with
plasma homocysteine levels in the highest tertile
showed a significantly higher all-cause mortality
risk (HR 1.7, 95 % CI 1.2–2.5, p = 0.003) as well as
a greater risk of fatal and nonfatal CHD (HR 1.8,
95 % CI 1.2–2.5, p = 0.001) compared to those with
low plasma homocysteine levels
- Study not originally designed to collect
blood samples for plasma
homocysteine level assessment, which
is why data could only be used from
two of the three PROSPER study sites
- Some blood samples have possibly
been stored at room temperature for
up to 8 h, which could have
contributed to artificially high plasma
homocysteine levels, and thus
misclassification
- Regarding all-cause mortality the pravastatin
treatment group showed an absolute risk reduction
of 4.6 % (95 % CI 0.78–8.4 %) in the subgroup with
high homocysteine levels compared to -0.66 % (95 %
CI -4.0–2.7) in the subgroup with low homocysteine
levels (absolute risk reduction difference of 5.2 %,
95 % CI 0.19–10.3; p = 0.04)
- No data about the intakte of vitamin B,
which may lower homocysteine levels
Waskiewicz et
al., 2012, [128]
Homocysteine Prospective observational, population-based




- In multivariable proportional hazards
models adjusted for sex, age and cardiovascular
risk factors, RR of all-cause long-term mortality
was significantly higher in plasma homocysteine
- The immunoenzymatic method used
to determine homocysteine levels in
this study has shown the lowest











Table 6 Summary of selected literature relevant to oxidative status in all-cause mortality prediction (Continued)
levels >10.51 umol/l compared to those <8.20 umol/l
(HR 1.766, 95 % CI 1.197–2.605)
comparative analyses of various
homocysteine assay methods
- In Kaplan-Meier survival curves patients with
homocysteine concentrations in the highest
tercile (>10.51 umol/l) showed significantly
increased long-term all-cause mortality compared
to subjects with homocysteine levels in the lowest
tercile (p = 0.0003)
- Impossible to perform analyses of
mortality related to stroke and
ischemic heart disease due to low
number of deaths in these groups
Naess et al.,
2013, [129]
Homocysteine Prospective, observational population-based






age of 47.8 years)
- After adjustment for age, sex and CRP levels,
Cox regression analysis – excluding patients
with stroke caused by dissection – showed high
plasma homocysteine levels (>9 ug/l) to be
significantly and independently associated with
all-cause mortality (HR 1.04, p = 0.02)
- Small sample size
- Possible selection bias due to
retrospective patient recruitment
- High plasma homocysteine levels
have been shown to be significant
all-cause mortality predictors only after
exclusion of patients with dissection,
suggesting homocysteine to be a










age of 69.4 years)
- Kaplan-Meier survival curves demonstrated a
significant lower survival in patients with total
plasma homocysteine levels and nutritional
status assessment (by mSGA) above the mean
level compared to lower levels (p = 0.04; survival
at 24 months = 50 %)
- Small sample size
Tekin et al.,
2012, [144]





< 35 %) (mean
age 60 +/− 12)
- Serum homocysteine levels were significantly
higher in non-survivors compared with survivors
(20.8 +/− 5.8 vs. 16.9 +/− 5.1 umol/l, p = 0.029)
- Small sample size
- With an optimal cut-off value of >17.45 umol/l,
the AUC of serum homocysteine levels with regard
to mid-term mortality prediction was 0.855 (95 % CI
0.792–0.965, p < 0.001)
AUC area under the receiver operating characteristic curve, CI confidence interval, CHD coronary heart disease, CKD chronic kidney disease, CRP C-reactive protein, CVD cardiovascular disease, GSB glutathione-S-
bimane, GSH glutathione, HF heart failure, HIMS Health in Men Study, HIV human immunodeficiency virus, HR hazard ratio, ICU intensive care unit, LASA Longitudinal Aging Study Amsterdam, mSGA modified
Subjective Global Nutritional Assessment, NAC N-acetylcysteine, NAHSIT Nutrition and Health Survey in Taiwan, OR odds ratio, p p-value are statistically significant at p < 0.05, PROSPER PROspective Study of Pravastatin











Table 7 Summary of selected literature relevant to sphingolipids and glycerophospholipids in all-cause mortality prediction
First author, year,
reference
Marker Study type Study population Key findings Limitations
Sigruener et al.,
2014, [132]
- Sphingomyelin Single-center, prospective
observational cohort-study
(median follow-up of 8 year)
2583 CAD-positve patients and 733
controls (LURIC Study)
- 9 PC species (PC 30:0, 30:1, 32:0, 32:1, 34:1,





- No information about
time of blood sampling
- Lysophosphati-
dylcholine
- PC 32:0 revealed the strongest positive association
with mortality
- 10 PC species (PC 38:3–38:7, 36:4, 36:5, 40:6, 40:7)
were significantly associated with a protective effect
- LysoPC 16:0, 18:0, and 18:2 were all associated with
a protective effect
- The 4 SM species 16:0, 16:1, 24:1, and 24:2 showed








102 patients with sepsis admitted
to the University Hospital of Regensburg
(Germany) and 56 healthy controls
- All 12 different lysoPC species and lysoPC-PC ratios
were markedly decreased in patients with sepsis




- No information about
causes of sepsis
- The 4 lysoPC species, C16:0, C:18:0, C18:1, and C18:2,





(median follow-up of 6 year)
1102 patients with CAD and 444 healthy
controls
- CAD patients showed higher plasma SM levels than
healthy controls (mean 51.8 vs. 44.9 mg/dl; p < 0.001)
- Only two-center study
- No autopsy performed
- In multivariate analysis, elevated SM (>48.1 mg/dl) was
related to cardiovascular death or nonfatal myocardial
infarction (HR 1.8, 95 % CI 1.0–3.3, p < 0.05) in patients
with ACS




556 patients scheduled for coronary
angiography in New York
- Patients with CAD had higher plasma SM concentrations
compared with non-CAD patients (median 52 vs. 44 mg/dl,
p < 0.0001)
- Only two-center study
- No prospective design
- The odds ratios for CAD patients for the third (2.83, 95 % CI
1.74–4.60, p < 0.0001) and fourth (2.59, 95 % CI 1.60–4.19,
p = 0.0001) quartiles were higher than the first quartile
ACS acute coronary syndrome, CAD coronary artery disease, CI confidence interval, HR hazard ratio, LURIC Ludwigshafen Risk and Cardiovascular Health study, Germany, lysoPC lysophosphatidylcholine, OR odds ratio,











thioester bond to coenzyme A (CoA). Carnitine trans-
ports long-chain acyl groups of fatty acids from the cel-
lular cytosol through the mitochondrial membrane. On
the outer mitochondrial membrane, carnitine acyltrans-
ferase l transfers acyl-CoA to the hydroxyl group of car-
nitine, resulting in acylcarnitine. The enzyme carnitine-
acylcarnitine translocase catalyzes the transport of acyl-
carnitine to the inner mitochondrial membrane where
carnitine acyltransferase II re-converts acylcarnitine to
acyl-CoA [137].
Current research (Table8 ) Metabolic profiling of 165
polar metabolites was performed in hemodialysis patients.
Individuals who died of a cardiovascular cause within 1 year
of initiating hemodialysis revealed markedly higher concen-
trations of the 4 long-chain acylcarnitines oleoylcarnitine,
linoleylcarnitine, palmitoylcarnitine, and stearoylcarnitine
compared with survivors who had undergone hemodialysis
for 1 year. Of these metabolites, oleoylcarnitine showed the
strongest association with cardiovascular mortality after
multivariable adjustment (Table 8) [138].
Conclusions
Since many uncertainties remain in predicting all-cause
mortality in patients hospitalized for CAP or for exacer-
bated COPD, additional prospective and retrospective
observational studies are needed to ascertain other
potential contributors to all-cause mortality in order to
improve the prediction of initial high risk. Metabolomic
analysis using MS may facilitate identification of
outcome-specific metabolite signatures that could poten-
tially generate new metabolic biomarkers of various
organic systems as all-cause mortality predictors in CAP
and in exacerbated COPD. Improvement in early and
accurate identification of high-risk patients can help
optimize short- and long-term management strategies in
LRTI and as a result, potentially improve survival, lead-
ing to a more cost-effective allocation of medical
Fig. 2 Metabolomics to improve outcome prediction in LRTI. Figure 2 shows the influence of different factors such as age, diseases, drugs,
environment, genetic factors, lifestyle and nutrition on endogenous metabolome which defines the human phenotype. The knowledge of metabolic
interactions may provide individual risk stratification, prediction of therapy response as well as new targets for future individual therapy and therefore a
form of personalized medicine. (Abbr.: TMAO, trimethylamine-N-oxide)
Table 8 Summary of selected literature relevant to acylcarnitines in all-cause mortality prediction
First author,
year, reference







I: 100 non-survivors of 1-year
HD and 100 survivors of at least
1-year HD matched for age, sex,
and race




ratio per SD 2.3, 95 % CI 1.4–3.8,
p = 0.001)
- Measurement of basline
metabolites after
starting hemodialysis
- Accuracy of ICD-9 codes
for cardiac diagnoses
not completely sensitive
or specificII: Oleoylcarnitine was
associated with cardiovascular
death (OR per SD 1.4, 95 % CI
1.1–1.9, p = 0.008)
II: 100 non-survivors of 1-year
HD and 200 survivors of at least
1 year HD
ArMORR The Accelerated Mortality on Renal Replacement Study, United States, CI confidence interval, HD hemodialysis, ICD-9 International Classification of
Diseases, OR odds ratio, p p-value are statistically significant at p < 0.05; SD, standard deviation
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resources. In addition, deeper knowledge of metabolic
interactions in LRTI may provide new targets for future
individual therapy and also be beneficial in predicting re-
sponses to therapy.
Abbreviations
ACTH: Adrenocorticotropic hormone; ADMA: Asymmetric dimethylarginine;
AKI: Acute kidney injury; Arg: L-arginine; AUC (or AUROC): Area under the
receiver operating characteristic curve; BODE: Body mass index, airflow
obstruction, dyspnea and exercise capacity index; CAP: Community-acquired
pneumonia; CE: Capillary electrophoresis; CHD: Coronary heart disease;
CI: Confidence interval; CKD: Chronic kidney disease; CoA: Coenzyme A;
COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; CURB-
65: New-onset confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/min,
systolic or diastolic blood pressure <90 mmHg or ≤60 mmHg, respectively,
age ≥65 years (pneumonia/LRTI risk scoring system); CVD: Cardiovascular
disease; DHEA: Dehydroepiandrosterone; DHEA-S: Dehydroepiandrosterone-
sulfate; DHT: Dihydrotestosterone; eGFR: Estimated glomerular filtration rate;
GC: Gas chromatography; GSB: Glutathione-S-bimane; GSH: Glutathione;
FACS: Fluorescence-activated cell sorter; FC: Free cortisol; FT: Free
testosterone; HD: Hemodialysis; HR: Hazard ratio; ICU: Intensive care unit;
IDO: Indoleamine-2,3-dioxygenase; Kyn: Kynurenine; LC: Liquid
chromatography; LRTI: Lower respiratory tract infection;
lysoPC: Lysophosphatidylcholine; MS: Mass spectrometry; NO: Nitric oxide;
NOS: Nitric oxide synthases; NT: Nitrotyrosine; NT-proBNP: Pro-B-type
natriuretic peptide; OR: Odds ratio; PC: Phosphatidylcholine;
PCT: Procalcitonin; PF: PaO2/FiO2; ProADM: Proadrenomedullin;
PSI: Pneumonia severity index; RNS: Reactive nitrogen species; ROC: Receiver
operating characteristics; ROS: Reactive oxygen species; SDMA: Symmetric
dimethylarginine; SM: Sphingomyelin; TC: Total cortisol; TT: Total
testosterone; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide;
Trp: Tryptophan; Tyr: Tyrosine.
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